- In March 2024, Cryo-Cell announced the spin-off of its subsidiary, Celle Corp., in a strategic move to enhance shareholder value. This decision aims to unlock new growth opportunities and streamline operations for both entities. The spin-off is expected to allow each company to focus on its core business, creating greater value for investors and stakeholders
- In February 2024, CooperSurgical®, a leader in fertility and women’s health, teamed up with Fulgent Genetics, Inc., a technology-driven company specializing in clinical diagnostics and therapeutic development. The partnership aims to provide families of Cord Blood Registry® (CBR®) with exclusive newborn genetic screening panels. This collaboration enhances CBR®'s offerings by incorporating advanced genetic testing, helping families make informed decisions about their children's health
- In February 2023, Americord, a prominent private stem cell bank, announced the successful release of cord blood stem cells to treat a client's grandmother in India for motor neuron disease. This progressive neurological disorder presents significant challenges for patients and their families. The use of cord blood stem cells in this case highlights the potential of stem cell therapies to offer innovative treatment options for complex health conditions
- In September 2023, CooperSurgical, a global leader in fertility and women's health, highlighted the significant role of Cord Blood Registry® (CBR®) at the annual Cord Blood Connect meeting, held from September 8th to 11th. This event, organized by the Cord Blood Association, brought together key stakeholders to promote both public and private newborn stem cell preservation. The Cord Blood Association, a nonprofit organization, works to advance the use of cord blood and birthing tissues in medical treatments, benefiting patients and advancing scientific progress
- In April 2022, Global Cord Blood Corporation revealed its plans to acquire Cellenkos, Inc., aiming for a 100% acquisition. The deal included the rights to develop and commercialize both current and future products, excluding those related to Cellenkos's ongoing collaboration with Incyte Corporation. This strategic acquisition is expected to enhance Global Cord Blood’s portfolio and expand its capabilities in stem cell-based therapies
